Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma
Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
There are 2 parts in this study.
The goal of Part 1 of this clinical research study is to confirm the highest tolerable dose
of pembrolizumab that can be given to patients with unresectable thymoma or thymic cancer.
The goal of Part 2 of this clinical research study is to learn if pembrolizumab given at the
dose that was found in Part 1 of the study can help to control thymoma or thymic cancer.
The safety of the study drug will be studied in both parts.
This is an investigational study. Pembrolizumab is FDA approved and commercially available
for treatment of many types of cancers. It is considered investigational to use pembrolizumab
to treat thymoma or thymic cancer.
The study doctor can describe how pembrolizumab is designed to work.
Up to 30 participants will be enrolled in this study. All will take part in MD Anderson.